ESCITALOPRAM Drug Interactions
Also known as: escitalopram
Escitalopram is a medication belonging to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat major depressive disorder and generalized anxiety disorder by helping to restore the balance of a natural substance called serotonin in the brain.ESCITALOPRAM has 12 documented drug interactions in our database, including 0 contraindicated, 0 major, 0 moderate, and 12 minor interactions.
0
Contraindicated
0
Major
0
Moderate
12
Minor
Escitalopram is a weak inhibitor of CYP2D6, the enzyme responsible for the metabolism of carvedilol. While a theoretical increase in carvedilol levels is possible, it is generally not considered clinically significant for most patients.
Mechanism
Carvedilol is primarily metabolized by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, which could theoretically reduce the metabolism of carvedilol, leading to increased plasma concentrations.
Clinical Management
Due to escitalopram's minimal CYP2D6 inhibition, significant dose adjustments for carvedilol are usually not required. Monitor patients for signs of increased beta-blockade, such as bradycardia or hypotension, especially if they are sensitive to carvedilol or have underlying cardiac conditions.
Atenolol and escitalopram are generally considered safe to co-administer. While both medications can independently cause bradycardia, the risk of a clinically significant additive effect is low due to their primary mechanisms and metabolic pathways.
Mechanism
Atenolol is primarily renally cleared, and escitalopram has minimal CYP2D6 inhibitory activity, thus pharmacokinetic interactions are unlikely. Any potential interaction would be pharmacodynamic, involving additive effects on heart rate, though this is generally not significant.
Clinical Management
Routine monitoring of heart rate and blood pressure is advisable, especially when initiating or adjusting doses of either medication. No specific dose adjustments are typically required for either drug when co-administered. Patients should be advised to report symptoms of excessive bradycardia or hypotension.
The interaction between nadolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal impact on nadolol's metabolism, and nadolol is primarily renally cleared.
Mechanism
Escitalopram is a weak inhibitor of CYP2D6, but nadolol is primarily eliminated renally with minimal CYP2D6 involvement, thus pharmacokinetic interaction is unlikely. A theoretical additive pharmacodynamic effect leading to bradycardia is possible, though not frequently observed.
Clinical Management
No specific dose adjustments are typically required for this combination. Monitor patients for signs of excessive bradycardia or hypotension, especially if they are sensitive to beta-blockers or have pre-existing cardiac conditions. If symptoms occur, consider adjusting the dose of either medication.
The interaction between pindolol and escitalopram is generally considered to be of minor clinical significance. Escitalopram has minimal CYP2D6 inhibition, which is the primary metabolic pathway for some beta-blockers, thus significantly elevated pindolol levels are unlikely. However, both drugs can independently cause bradycardia, so an additive pharmacodynamic effect is theoretically possible.
Mechanism
Pindolol is metabolized primarily by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, therefore, clinically significant pharmacokinetic inhibition of pindolol metabolism is not expected. Both drugs can exert bradycardic effects, leading to a potential, though unlikely, additive pharmacodynamic effect.
Clinical Management
No specific dose adjustments are typically required. Monitor patients for signs of excessive beta-blockade, such as bradycardia, hypotension, or dizziness, especially during initiation or dose changes of either medication. If symptoms occur, consider dose reduction of pindolol or alternative agents.
The interaction between nebivolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal CYP2D6 inhibitory activity, suggesting a low risk of significantly increased nebivolol plasma levels.
Mechanism
Nebivolol is metabolized by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, so it is unlikely to cause a clinically significant increase in nebivolol concentrations. Both drugs can cause bradycardia through different pharmacodynamic mechanisms (beta-blockade for nebivolol, serotonergic effects for escitalopram, though direct bradycardic effect of escitalopram is less common).
Clinical Management
Routine monitoring for additive pharmacodynamic effects like bradycardia and hypotension is advisable, especially when initiating or adjusting doses of either medication. No specific dose adjustments are typically required for either drug due to this interaction, but individual patient response should guide therapy. If bradycardia or hypotension occurs, consider dose reduction or alternative agents.
The interaction between labetalol and escitalopram is generally considered to be of minor clinical significance. While both drugs can independently cause bradycardia, escitalopram is not a significant inhibitor of CYP2D6, the primary metabolic pathway for many beta-blockers, including labetalol.
Mechanism
Labetalol is metabolized primarily by CYP2D6. Escitalopram is a weak inhibitor of CYP2D6, meaning it is unlikely to significantly alter labetalol plasma concentrations. Both drugs can independently cause bradycardia, leading to a theoretical additive pharmacodynamic effect, though this is less common with escitalopram.
Clinical Management
Generally, no specific dose adjustments or enhanced monitoring are required for this combination. However, clinicians should remain aware of the potential for additive bradycardia, especially in patients with pre-existing cardiac conditions or those on other bradycardia-inducing medications. Monitor vital signs as clinically indicated, particularly heart rate.
Escitalopram has minimal inhibitory effects on CYP2D6, the primary enzyme metabolizing metoprolol. Therefore, a clinically significant pharmacokinetic interaction leading to increased metoprolol levels is unlikely. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible.
Mechanism
Metoprolol is primarily metabolized by CYP2D6. Escitalopram is a weak or negligible inhibitor of CYP2D6, suggesting minimal pharmacokinetic impact on metoprolol clearance. Both metoprolol (beta-blocker) and escitalopram (SSRI, which can affect heart rate) can cause bradycardia through different pharmacodynamic pathways.
Clinical Management
Routine co-administration generally does not require specific dose adjustments. Monitor patients for signs of excessive bradycardia or hypotension, especially if they are sensitive to either medication or have pre-existing cardiac conditions. If bradycardia occurs, consider dose reduction of either agent or an alternative antidepressant with no CYP2D6 interaction.
Escitalopram is a weak inhibitor of CYP2D6, the primary enzyme metabolizing metoprolol. Therefore, a clinically significant increase in metoprolol plasma levels is generally not expected, unlike with potent CYP2D6 inhibitors such as fluoxetine or paroxetine. However, additive pharmacodynamic effects on heart rate and blood pressure are theoretically possible.
Mechanism
Escitalopram is a weak inhibitor of cytochrome P450 2D6 (CYP2D6), which is the main metabolic pathway for metoprolol. While pharmacokinetic interactions are unlikely to be significant, both drugs can independently cause bradycardia, leading to a potential additive pharmacodynamic effect.
Clinical Management
Routine co-administration of metoprolol and escitalopram generally does not require specific dose adjustments or enhanced monitoring for pharmacokinetic interactions. However, clinicians should monitor patients for signs of excessive beta-blockade, such as bradycardia or hypotension, especially when initiating or titrating either medication.
The interaction between bisoprolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal impact on the metabolism of bisoprolol, which is primarily renally cleared.
Mechanism
Bisoprolol is primarily eliminated renally with minimal CYP2D6 involvement. Escitalopram has minimal CYP2D6 inhibitory activity, therefore, it is unlikely to significantly alter bisoprolol plasma concentrations. An additive pharmacodynamic effect leading to bradycardia is theoretically possible but rarely clinically significant.
Clinical Management
Generally, no specific dose adjustments are required. Monitor patients for signs of excessive bradycardia or hypotension, especially when initiating or adjusting doses of either medication. If significant bradycardia occurs, consider dose reduction of one or both agents or alternative therapies.
The interaction between propranolol and escitalopram is generally considered minor. While both drugs can independently cause bradycardia, escitalopram has minimal CYP2D6 inhibitory effects, thus not significantly altering propranolol's metabolism.
Mechanism
Escitalopram is a weak inhibitor of CYP2D6, the primary enzyme responsible for the metabolism of propranolol. Therefore, escitalopram is unlikely to cause a clinically significant increase in propranolol plasma concentrations. Both drugs can independently cause bradycardia, leading to a potential additive pharmacodynamic effect.
Clinical Management
Generally, no special precautions or dose adjustments are required when co-administering propranolol and escitalopram. However, clinicians should monitor for signs of excessive bradycardia, especially in sensitive patients or those with pre-existing cardiac conditions. If bradycardia occurs, consider dose reduction of either agent or alternative therapies.
There is generally no significant pharmacokinetic interaction between timolol and escitalopram. Both drugs can independently cause bradycardia, so an additive pharmacodynamic effect resulting in a slight increase in bradycardia risk is theoretically possible, but clinically unlikely to be significant.
Mechanism
Escitalopram is a weak inhibitor of CYP2D6, the primary enzyme metabolizing many beta-blockers. However, timolol is primarily metabolized by CYP2D6 and CYP2C19, and escitalopram's weak inhibition of these enzymes is not expected to significantly alter timolol's plasma levels. Both agents can cause bradycardia through different mechanisms, leading to a theoretical additive pharmacodynamic effect.
Clinical Management
No specific dose adjustments are typically required when co-administering timolol and escitalopram. Monitor patients for signs of excessive bradycardia, especially if they are sensitive to beta-blockers or have underlying cardiac conditions, although this is generally not a common concern with this combination.
The interaction between acebutolol and escitalopram is generally considered minor. Escitalopram has minimal CYP2D6 inhibitory activity, therefore, it is unlikely to significantly alter acebutolol plasma levels. However, both drugs can independently cause bradycardia, and an additive pharmacodynamic effect is theoretically possible.
Mechanism
Escitalopram is a weak inhibitor of CYP2D6, the enzyme responsible for the metabolism of some beta-blockers. Acebutolol is partially metabolized by CYP2D6, but escitalopram's weak inhibition is unlikely to cause a clinically significant pharmacokinetic interaction. A theoretical additive pharmacodynamic effect on heart rate is possible due to both drugs' potential to induce bradycardia.
Clinical Management
No specific dose adjustments are typically required for this combination. Monitor patients for signs of excessive bradycardia (e.g., heart rate <50 bpm, dizziness, fatigue), especially at the initiation of escitalopram or after dose increases. If significant bradycardia occurs, consider dose reduction of acebutolol or an alternative antidepressant with no cardiac effects.
For complete prescribing information:
View full ESCITALOPRAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.